Clinical trials: Cancer Patients and Physical Activity
Squamous Cell Carcinoma of the Head and Neck
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
This is an open label pilot study evaluating the pharmacodynamics and safety of single agent olaparib administered at 300mg bid (twice a day) for 14 days orally in patients with human papillomavirus (HPV) -positive and human…
- Trial name
- NCT02686008
- Testing
- Olaparib
- Sponsor
- Yale University
Exercise, Neoplasms
Monitoring and Telecoaching of Physical Activity in Patients With Stage III and IV Non-small Cell Lung Cancer
This study is a prospective non-randomised control study to evaluate the efficacy of a physical activity promotion program on the experience of physical activity in patients with stage III and IV non-small cell lung cancer…
- Trial name
- NCT03883243
- Testing
- Telecoaching
- Where
- Belgium
- Volunteers
- 32 people
- Sponsor
- KU Leuven
Neoplasms
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
This is an open-label, multicenter study designed to assess the safety, pharmacokinetics, pharmacodynamics, and therapeutic activity of emactuzumab and RO7009789 administered in combination in participants with locally advanced…
- Trial name
- NCT02760797
- Testing
- Emactuzumab, RO7009789
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Fat Metabolism Following Chemotherapy in Breast Cancer
Following chemotherapy, breast cancer patients primarily gain fat mass and lose muscle mass. Both depletion of muscle and an increase of fat mass in breast cancer patients are related to short survival, and decreased skeletal…
- Trial name
- NCT01890824
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Locally Advanced Head and Neck Squamous Cell Carcinoma
Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment
This clinical trial examines a group-mediated cognitive behavioral resistance exercise intervention in head and neck cancer patients who are undergoing chemoradiation treatment.
- Trial name
- NCT04733495
- Testing
- Counseling, Dietary Counseling and Surveillance, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic (Stage IV) Melanoma
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
Although treatments for breast cancer have improved, 20-30% of patients with early disease develop metastases (cancer that spreads to other parts of the body).
- Trial name
- EPIBREAST (NCT07340619)
- Testing
- prifetrastat monotherapy for 15 days then combination with fulvestrant, prifetrastat in combination with fulvestrant
- Where
- 8 sites in France
- Volunteers
- 51 people
- Sponsor
- UNICANCER
Acute Myeloid Leukemia (AML)
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective oral venetoclax is in participants with AML .
- Trial name
- NCT04826523
- Where
- 10 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- AbbVie
Non-Small Cell Lung Cancer Metastatic
Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC
This is an open -label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination with durvalumab in patients advanced NSCLC who progressed following…
- Trial name
- NCT03732274
- Testing
- TEW-7197
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- MedPacto, Inc.
Head and Neck Neoplasms, Physical Inactivity
Preventive Physical Activity Intervention in Head and Neck Cancer
The study includes patients with tumors of the oropharynx, larynx and hypopharynx scheduled to receive radiotherapy with curative intent (+/- chemotherapy).
- Trial name
- NCT05432297
- Testing
- Preventive physical exercise
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Sahlgrenska University Hospital
Prostate Cancer
Lifestyle Intervention in Patients With Metastatic Prostate Cancer
The proposed pilot study aims at determining the feasibility of a lifestyle intervention including adherence to a personalised dietary regimen combined with regular physical activity in patients newly diagnosed with prostate…
- Trial name
- ACTIDIET-PRO (NCT05850182)
- Testing
- Lifestyle intervention
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Oncology Institute of Southern Switzerland
Colon Cancer Liver Metastasis
Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases.
- Trial name
- LINK (NCT03370198)
- Testing
- NKR-2 cells
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Celyad Oncology SA
Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine…
- Conditions
- Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma, Advanced Pancreatic Carcinoma, Advanced Colorectal Carcinoma
- Trial name
- NCT05759923
- Testing
- OATD-02
- Where
- 3 sites in Poland
- Volunteers
- 40 people
- Sponsor
- Molecure S.A.
Non-Hodgkin Lymphoma
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
This is a monocentric, prospective phase II trial addressing safety and capability to prevent grade-4 Chemotherapy-induced Thrombocytopenia (CIT) of romiplostim in patients with NHL.
- Trial name
- ProRom (NCT01516619)
- Testing
- Romiplostim
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Andres J. M. Ferreri
Non-Hodgkin Lymphoma
EMD 521873 in Advanced Solid Tumors, MTD Finding
Primary trial objective in this three arm trial is to assess the safety and tolerability of EMD 521873, and to determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or…
- Trial name
- NCT01032681
- Testing
- EMD 521873
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Glioblastoma
Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma
Glioblastoma is a brain tumor with a very poor prognosis, affecting around 2,400 new patients every year. Current treatments do not provide good control of the disease.
- Trial name
- BOOSTCAR (NCT06764537)
- Testing
- Blood collection
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Central Hospital, Nancy, France
Breast Cancer
ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
The primary objective is to assess the event-free survival defined as the time from randomisation to progression, death without progression, loss to follow up, whichever occurred first..
- Trial name
- ZACFAST (NCT00752986)
- Testing
- ZD6474 (Vandetanib at the dose of 100 mg), Fulvestrant, ZD6474 (Vandetanib at the dose of 300 mg)
- Where
- 11 sites in Italy
- Volunteers
- 39 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Overweight or Obese Breast Cancer Patients
Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer
The primary objective of MEDEA is to compare the effect of a personalised telephone-based health education weight loss program based on motivational coaching, exercise and diet versus a standard health educational program control…
- Trial name
- MEDEA (NCT04304924)
- Testing
- The personalized telephone based intervention
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Non-Small Cell Lung Cancer
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic…
- Trial name
- KRAScendo 170 (NCT05789082)
- Testing
- Divarasib, Pembrolizumab, Carboplatin
- Where
- 71 sites in United States, Argentina and 16 more
- Volunteers
- 320 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.